Embecta

Embecta develops and manufactures insulin delivery devices for people with diabetes, including pen needles, insulin syringes, and related accessories. The company was spun off from Becton Dickinson (BD) in 2022 and serves more than 30 million people in over 100 countries. It trades publicly on Nasdaq under the ticker EMBC.